InMed Pharmaceuticals, Inc. (OTCQB: IMLFF), a pre-clinical stage biopharmaceutical company that specializes in the development of therapies through research and development into the pharmacology of cannabinoids and drug delivery systems, continues to get positive media coverage of ongoing operational developments, propelled by the company’s impressive leadership team.
Insider Financial highlighted InMed Pharmaceuticals as a “Cannabis Runner” in an article back in January, stating that “This is the kind of company that needs to maintain a positive news flow in order to keep investors interested.” More recently, Forbes released an article describing the company as “more than just another cannabis drug company”. This was due to the excitement surrounding the development of its proprietary cannabinoid manufacturing system and sought-after database, its biosynthesis for cannabinoids that is similar to that used to create synthetic insulin, as well as its ability to leverage some of the leading experts in the pharmaceutical industry.
Although the company’s pipeline is expected to generate a significant amount of attention in 2018, InMed Pharmaceuticals’ manufacturing system and database are catching the eye of investors and biotech companies. THC and CBD have, of course, been used for treating medical conditions, but there are now more than 90 different cannabinoids identified in one plant, and all of these are thought to serve various purposes. InMed has managed to plug these different cannabinoids into its system, allowing the bioinformatics compounds to test them against various illnesses and drug compounds, matching the right cannabinoids to help fight specific diseases.
This tool has helped the company identify two therapies, one for epidermolysis bullosa (EB), a rare skin disease found in children, and one for glaucoma, a degenerative condition that causes damage to a person’s optic nerve. In addition to all of the above, the company has now developed a method of biosynthesis similar to that used to create synthetic insulin, but for cannabinoids. This process is not only cheaper, but quicker, and it gives access to cannabinoids that are not currently profitable to turn into drugs.
These are all developments that owe their success to leadership that comprises some of the world’s most experienced professionals in the pharmaceutical, drug discovery, cannabinoid therapy, and R&D industries (http://dtn.fm/DTx95).
For more information, visit the company’s website at www.InMedPharma.com
Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.